TLX.AX Telix Pharmaceuticals Limited
Company Analysis
Latest News
🔴 Telix Pharmaceuticals is trading 5.58% down today after profit-taking following Pixclara’s FDA approval
Telix Pharmaceuticals is trading 5.58% down now at A$16.76 as investors take profits following Pixclara’s FDA approval. - The approval remains a major...
🟢 Telix Pharmaceuticals is trading 9% up today after FDA approves Pixclara for glioma imaging
Telix Pharmaceuticals is trading 8.63% up at A$17.75 after the U.S. FDA approved Pixclara on September 14, 2026. - Pixclara is the first FDA-approved FET-PET...
🟢 Telix Pharmaceuticals is trading 10% up today after FDA approves Pixclara for glioma
Telix Pharmaceuticals is trading 10.10% up now at A$17.99 after the U.S. FDA approved Pixclara on September 14, 2026. - Pixclara is the first FDA-approved...
🟢 Telix Pharmaceuticals is trading 5% up today after FDA approval of Pixclara for glioma
Telix Pharmaceuticals is trading at A$17.18 (+5.14%) after the U.S. FDA approved Pixclara on September 14, 2026. • Pixclara became the first FDA-approved...
Telix Wins First-Ever FDA Nod for a Brain Cancer Imaging Drug — But Can It Turn Regulatory Victory Into Revenue?
Shares of Telix Pharmaceuticals surged 8.4% to A$16.99 on September 14 after the U.S. FDA approved Pixclara, a PET imaging drug that helps doctors distinguish...
🟢 Telix Pharmaceuticals is trading 8.42% up today after FDA approval of Pixclara for glioma
Telix Pharmaceuticals is trading A$16.99, +8.42% after the U.S. FDA approved Pixclara on September 14, 2026, as the first FDA-approved FET-PET imaging drug for...
🔴 Telix Pharmaceuticals is trading 6.5% down today despite Pixclara FDA approval on September 14, 2026
Telix Pharmaceuticals is trading 6.5% down at A$15.67 despite the U.S. FDA approving Pixclara on September 14, 2026, as the first FDA-approved FET-PET imaging...
🔴 Telix Pharmaceuticals is trading 6.09% down today with no clear company-specific catalyst identified
Telix Pharmaceuticals is trading at A$15.74, -6.09%, with no clear company-specific announcement identified for September 11, 2026. • Recent updates include...
🟢 Telix Pharmaceuticals is trading 4.08% up today after BiPASS enrollment and FDA NDA pathway alignment
Telix Pharmaceuticals is trading 4.08% up at A$16.33 after completing patient enrollment in the Phase 3 BiPASS study and aligning with the FDA on a potential...
🟢 Telix Pharmaceuticals is trading 4.19% up today; specific catalyst remains unconfirmed
Telix Pharmaceuticals is trading 4.19% up at A$15.91, with no confirmed catalyst identified for the gain. - David Gill will become Chair effective September...
🔴 Telix Pharmaceuticals is trading 4.15% down today with no new announcement explaining the decline
Telix Pharmaceuticals is trading at A$15.49, down -4.15%, with no new announcement dated August 26, 2026 explaining the decline. - The company’s news page...
🔴 Telix Pharmaceuticals is trading 4.08% down today; specific catalyst remains unclear
Telix Pharmaceuticals is trading 4.08% down at A$15.50, following a close of A$16.16 on August 25, 2026, as the specific catalyst remains unclear. - Searches...
🟢 Telix Pharmaceuticals is trading 4.74% up today after half-year revenue and EBITDA growth
Telix Pharmaceuticals is trading 4.74% up at A$16.36 after its August 20 half-year results showed US$477 million revenue and US$52 million adjusted EBITDA. -...
🔴 Telix Pharmaceuticals is trading 10.13% down today
Telix Pharmaceuticals is trading at A$15.62, down -10.13%, with no specific August 24 catalyst confirmed. - The August 24, 2026 decline follows Telix’s August...
🔴 Telix Pharmaceuticals is trading 6.27% down today as biotech weakness outweighed positive reaction to results
Telix Pharmaceuticals is trading 6.27% down at A$16.29 as broader biotech weakness outweighed the positive reaction to its August 20, 2026 half-year...
🟢 Telix Pharmaceuticals is trading 4.28% up today after strong first-half 2026 results
Telix Pharmaceuticals is trading A$17.56, 4.28% up after reporting strong first-half 2026 results on August 20, 2026. - Revenue rose 22% year-over-year to...
Telix Hits the Billion-Dollar Revenue Threshold — But Can Its Imaging Cash Cow Fund an Expensive Leap Into Cancer Therapy?
Shares surged 7.6% to A$16.19 as investors continued digesting Telix Pharmaceuticals' strongest quarterly report yet, raising a pointed question: whether a...
🟢 Telix Pharmaceuticals is trading 7.65% up today after Q2 revenue rose 21% and outlook improved
Telix Pharmaceuticals is trading 7.65% up at A$16.19 after investors continued absorbing strong second-quarter results and an improved full-year outlook. - Q2...